Mitochondria blog

Stealth casts a wide net with experimental treatment for mitochondrial diseases

Source: MedCityNews

Image: GettyImages


At first glance, primary mitochondrial diseases are an incredibly hard target for biopharma companies to pursue.

There are literally hundreds of different subtypes, caused by mutations in either nucleic DNA (nDNA) or mitochondrial DNA (mDNA). Even within that, patients that carry the same mutations (genotypes) often have variable symptoms and disease characteristics (phenotypes).


Read more here

Leave a Reply